Pri­ma­ry care start­up For­ward rais­es $100M to grow na­tion­al­ly with self-ser­vice ‘Care­Pods’

Last year
Startups
Health Tech

NMD Phar­ma se­cures €75M from in­sid­ers for three PhII tri­als in neu­ro­mus­cu­lar dis­or­ders

Last year
Financing
Startups

Backed by ex-Google CEO Er­ic Schmidt, a new non­prof­it looks to 'solve sci­ence' with AI

Last year
AI

Graphite Bio hands Nas­daq spot to pres­by­opia biotech Lenz Ther­a­peu­tics as PhI­II read­outs loom

Last year
Deals

Scoop: Smart Im­mune tar­gets $54M Se­ries A to ad­vance T cell prog­en­i­tor ther­a­py: #Jef­feries23

Last year
Financing
Cell/Gene Tx

Three months af­ter big re­or­ga­ni­za­tion, an­ti­body mak­er Atre­ca is back with an­oth­er round of lay­offs

Last year
People

Gilead­'s Kite dou­bles down on Ar­cel­lx's blood can­cer cell ther­a­pies with $285M

Last year
Deals
Cell/Gene Tx

Mur­al On­col­o­gy spins out from Alk­er­mes with $275M and a lead im­munother­a­py pro­gram

Last year
Financing
Startups

Ex­clu­sive: NTx rais­es $47.5M Se­ries B to com­mer­cial­ize pro­tein, mR­NA man­u­fac­tur­ing plat­forms 

Last year
Financing
Manufacturing

Sanofi-backed T-Ther­a­peu­tics bags $59M in Se­ries A to un­lock po­ten­tial of TCR ther­a­peu­tics: #Jef­feries23

Last year
Financing
Startups

Pfiz­er to cut 500 jobs at Sand­wich, UK site

Last year
People
Pharma

Ama­zon lands FDA warn­ing let­ter over dis­tri­b­u­tion of sev­en un­ap­proved eye drops

Last year
FDA+

New NIH chief stress­es fo­cus on obe­si­ty, clin­i­cal tri­al chal­lenges

Last year
Pharma
FDA+

How vi­ral Tik­Tok trends are catch­ing on in phar­ma mar­ket­ing

Last year
Marketing

Verve won tri­al suc­cess with a gene-edit­ing mile­stone. Why don't in­vestors like it?

Last year
R&D
Cell/Gene Tx

Almi­rall’s new AI deal with Ab­sci; Jazz part­ners with Au­ti­fony; SAB rais­es $67M

Last year
News Briefing

Eye­Bio dou­bles the size of its Se­ries A as an­ti-VEGF vet­er­ans seek new ways of treat­ing reti­nal dis­eases

Last year
Financing
Startups

FDA touts new au­thor­i­ty as ODAC hosts ad­comm to re­view de­layed con­fir­ma­to­ry tri­als for ac­cel­er­at­ed ap­provals

Last year
FDA+

No­var­tis adds to mul­ti­ple scle­ro­sis 'Love Sto­ry' cam­paign with more pa­tient per­spec­tives

Last year
Pharma
Marketing

Mar­ket­ingRx roundup: Vi­a­tris de­buts new cam­paign in Times Square; As­traZeneca re­news nat­ur­al gas deal

Last year
Pharma
Marketing

MBrace Ther­a­peu­tics cap­i­tal­izes on ADC wave with $85M Se­ries B to en­ter the clin­ic this quar­ter

Last year
Financing
Startups

Why An­dreessen Horow­itz's Vi­nee­ta Agar­wala sees com­mu­ni­ca­tion as the next op­por­tu­ni­ty for AI in health­care

Last year
Health Tech

As­traZeneca's con­cur­rent Imfinzi-chemo-ra­di­a­tion com­bo in lung can­cer miss­es pri­ma­ry end­point in PhI­II tri­al

Last year
R&D
Pharma

The­seus Phar­ma­ceu­ti­cals lays off most work­ers and seeks 's­trate­gic al­ter­na­tives' af­ter can­cer pipeline fail­ure

Last year
People
R&D
First page Previous page 245246247248249250251 Next page Last page
A service from the Financial Times